Fundraising Fox

BioVersys

Basel, CH · Founded 2010 · 41 employees on LinkedIn · 3 known investors

BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections. The company targets infectious disease indications with next-generation antimicrobial treatments.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

BioVersys was founded in 2010 by Dr. Marc Gitzinger.

DM
Dr. Marc GitzingerChief Executive Officer & Founder

Investors · 3

AMR Action FundBoston
StartAngels NetworkZürich

Also in the syndicate · 1

GSK plc

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026 - BioSpacebiospace.com · Apr 2026BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024 - BioSpacebiospace.com · Mar 2025BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million - BioSpacebiospace.com · May 2024AMR Action Fund invests in Swiss antibiotic maker | CIDRAPcidrap.umn.edu · Jan 2023

Frequently asked questions

What does BioVersys do?
BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections. The company targets infectious disease indications with next-generation antimicrobial treatments.
Who founded BioVersys?
BioVersys was founded by Dr. Marc Gitzinger in 2010.
Who are BioVersys's investors?
BioVersys's investors include AMR Action Fund, StartAngels Network.
Where is BioVersys headquartered?
BioVersys is headquartered in Basel, CH.